Merck Reports Discontinuation Of Phase 3 KeyVibe-008 Trial Based On Recommendation Of An Independent Data Monitoring Committee
Portfolio Pulse from Benzinga Newsdesk
Merck has announced the discontinuation of its Phase 3 KeyVibe-008 trial based on the recommendation of an independent data monitoring committee. The trial did not meet the primary endpoint of overall survival and showed higher rates of adverse events in the treatment arm.
August 08, 2024 | 10:47 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Merck has discontinued its Phase 3 KeyVibe-008 trial after it failed to meet the primary endpoint of overall survival and showed higher rates of adverse events in the treatment arm. This could negatively impact investor sentiment in the short term.
The discontinuation of the trial indicates that the treatment was not effective and had higher adverse events, which is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100